Primary Image

generic image

Clinical Trial

A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects

IRB Protocol Number STU00219033

Contact

nvg@sralab.org

Objective

This study is examining how the study drug, NVG-291, affects nerve connections in the spinal cord and whether it is safe and tolerable to use.

Volunteers in this study will:

  • Participate in study visits over 16 weeks.
  • Visits will take place at the Shirley Ryan 嫩B研究院.

Visit involves:  

  • Non-invasive stimulation of the brain and spinal cord and startle acoustic stimuli.
  • Upper and lower limb training
  • Answer questionnaire
  • Physiological and physical assessments
  • Receiving daily injections of NVG-291 or placebo.

Who Can Participate

Participants with a spinal cord injury who are:

  • Between 18-75 years of age 
  • Sustained a spinal cord injury at C1-C7 (1 -10 years post injury) 
  • In good physical health 
  • Proficiency in English

Compensation

Receive compensation

Apply for this Trial

Your information will not be published.

All fields are required.

Featured Quote

More Studies

Brain-Based and Clinical Phenotyping of Pain Pharmacotherapy in Knee Osteoarthritis (PREDICT)

This is a clinical trial of people who have pain due to knee osteoarthritis at Northwestern University Feinberg School of Medicine in collaboration with Shirley Ryan 嫩B研究院. The study will last for about 20 weeks. 180 qualified participants will be randomly assigned in a 1:1:1 ratio (60 participants per group) to one of three treatment groups: duloxetine, celecoxib or placebo. Participants will have an X-ray, knee MRI, brain MRI, blood draws, pain sensitivity testing and will be asked to fill out questionnaires. The purpose of this study is to predict which participants will respond to the treatment.

read more
view all

Latest Updates

view all